P.S. This former CIA advisor says the Dems already have Biden’s replacement – a shadow candidate hand-selected to defeat Trump. See full details HERE now.
Thank you for subscribing to Insider Trades Daily, which covers the most recent insider buying and selling activity from Wall Street CEO's, CFO's, COO's and other insiders.
This message is a paid advertisement sent on behalf of Paradigm Press, a third-party advertiser of InsiderTrades.com and MarketBeat.
This ad is sent on behalf of Paradigm Press, LLC, at 1001 Cathedral St., Baltimore, MD 21201. If you're not interested in this opportunity from Paradigm Press, LLC, please click here to remove your email from these offers.
If you have questions about your subscription, feel free to contact our U.S. based support team via email at contact@marketbeat.com.
If you no longer wish to receive email from InsiderTrades.com, you can unsubscribe.
I wanted to write you and let you know that tomorrow is the last day that your account is eligible for our new member discount. ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
Good day -
I wanted to write you and let you know that tomorrow is the last day that your account is eligible for our new member discount.
If you register for MarketBeat All Access by tomorrow night at 11:59 PM Pacific Time, you can get a completely-free 30-day subscription to MarketBeat All Access.
If you want to continue your premium subscription after your 30-day trial, we'll apply a $200 account credit to your account. That means your first year's subscription is just $199 (normally $399).
MarketBeat's All Access subscription gives you access to our premier research platform that includes MarketBeat Daily Premium, portfolio monitoring tools (My MarketBeat), MarketBeat's full suite of research tools and stock screeners, a real-time news feed, email, and SMS alerts, the MarketBeat Idea Engine, extended data export tools, and much more. You will also get access to our full database of more than 1,000,000 analyst recommendations, our proprietary broker performance and accuracy ratings, and other exclusive benefits.
P.S. If you have questions about MarketBeat All Access, just hit reply to this email. Our team would love to hear from you and answer any questions you might have.
Thank you for subscribing to Earnings360, a morning newsletter that summarizes quarterly earnings for public companies that trade on U.S. markets.
If you have questions about your subscription, feel free to contact our U.S. based support team via email at contact@marketbeat.com.
If you no longer wish to receive email from Earnings360, you can unsubscribe.
Thank you for subscribing to DividendStocks.com's daily newsletter for dividend and income investors that covers ex-dividend stocks, new dividend declarations, dividend stock ideas, and the latest market news.
This message is a paid advertisement sent on behalf of InvestorPlace, a third-party advertiser of DividendStocks.com and MarketBeat.
If you have questions about your subscription, feel free to contact our U.S. based support team via email at contact@marketbeat.com.
If you no longer wish to receive email from DividendStocks.com, you can unsubscribe.
I’ve spoken out against critical race theory, the climate change agenda, the Covid lockdowns, and financial fraud at the heart of some of America’s most storied companies and institutions.
For daring to question the establishment's narrative, I’ve been tarred as a bigot, a conspiracy theorist, and every other “ist” and “ism” under the sun… but I don’t care.
I feel it’s my moral obligation to speak truth to power, despite the risks to my reputation, my business, and my own welfare.
It involves a hidden group that has done more to destroy the political, social, and economic fabric of our country than any other.
I’m not talking about an ethnic group, religious group, or even a political party – this unelected group operates in the shadows yet wields more power than anyone else in America.
For decades, they’ve quietly been solidifying their power.
Now, they’ve established a near-permanent stranglehold on our country.
It’s a plan that, if successful, could be more financially devastating than the 2008 financial crisis… and more consequential to your freedoms than the COVID lockdowns.
That’s why if you have any savings in the bank or own any stocks and assets, you must watch my new documentary before it’s too late.
JP Morgan analysts have pegged the future price of oil at $380.....................................................................................................................................................................................................................................................................................................................
It's NOT oil stocks, futures, or anything you've likely heard about.
Rather, it's an unusual investment that could hand you huge monthly income from the oil and gas markets.
In fact, one man used it build a small $1,000 investment into a $100,000 income stream over fifty years.
All the details are right here from my colleague, income expert Marc Lichtenfeld:
Sincerely,
Rachel Gearhart Associate Publisher, The Oxford Club
This ad is sent on behalf of The Oxford Club, 105 W. Monument Street Baltimore, MD 21201. If you would like to opt out from receiving offers from The Oxford Club, please click here
This is a PAID ADVERTISEMENT provided to the subscribers of StockEarnings Free Newsletter. Although we have sent you this email, StockEarnings does not specifically endorse this product nor is it responsible for the content of this advertisement. Furthermore, we make no guarantee or warranty about what is advertised above.
Your privacy is very important to us, if you wish to be excluded from future notices, do not reply to this message. Instead, please click Unsubscribe .
StockEarnings, Inc 33 SE 4th St, Suite 100, Boca Raton, FL 33432 USA W: 877.6.STOCKS StockEarnings.com
This is a PAID ADVERTISEMENT provided to the subscribers of StockEarnings Free Newsletter. Although we have sent you this email, StockEarnings does not specifically endorse this product nor is it responsible for the content of this advertisement. Furthermore, we make no guarantee or warranty about what is advertised above.
Your privacy is very important to us, if you wish to be excluded from future notices, do not reply to this message. Instead, please click Unsubscribe .
StockEarnings, Inc 33 SE 4th St, Suite 100, Boca Raton, FL 33432 USA W: 877.6.STOCKS StockEarnings.com
Bounce Alert: 3 Large Caps With RSIs Too Good To Ignore
Savvy stock investors often look for bargains using the Relative Strength Index (RSI). This technical tool evaluates a stock's performance over the last 14 days and assigns a value from 0 to 100. Compared to many other technical indicators out there, the RSI is easy to read: anything above 70 suggests a stock may be overbought, while one below 30 indicates oversold conditions. The more extreme the reading, the stronger the underlying conviction.
The past week has seen a strong rebound across equities. After a little wobble during the first half, investors were getting nervous. This uptick, reflecting a revived risk-on sentiment in the face of stubborn inflation readings, is drawing investors back.
But not all stocks are rallying -- at least not yet. The sudden divergence has made it particularly clear that some laggards, those with ultra-low RSI readings, might just be too good to ignore. Let's take a look at three such companies.
As a big and bulky defensive stock, shares of healthcare titanCVS Health Corporation (NYSE: CVS) will never have the agility or speed that their peers in the tech space do. Because shares had been trending down through much of April, their earnings-inspired 20% plunge last week was unexpected.
The stock's biggest one-day drop for more than a decade came about after the company reported dismal earnings that missed analyst expectations across the board. It didn't help that management's forward guidance for the year ahead was cut in the face of rising medical costs.
However, with an RSI that dropped as low as 13 at one point in the past week, there's a case to be made that this initial drop is way overextended. With CVS shares continuing to consolidate above last week's low and the RSI starting to rise, it's starting to feel like the bears might be running out of steam. This might not be a stock to be backing for the long term, at least not yet, but we could be looking at a near-term bounce back from the depths.
2. Bristol-Myers Squibb Company
Another stock that will never light investors' imaginations on fire, Bristol-Myers Squibb Company (NYSE: BMY) shares touched off multi-year lows last week. The pharmaceutical manufacturer has been trending down since 2022's all-time high, but the most recent leg down took it into way oversold territory.
Like with CVS, Bristol-Myers shares continue to consolidate above last week's low, with a solid up day on Thursday boding well for the coming weeks. The stock's RSI has already moved up from 22 to the low 30s, and while it's technically out of oversold territory, that doesn't take away from its bounce potential.
Investors should watch for shares to hold onto yesterday's gains going into the weekend, with an open above $45 likely the precursor to a strong bounce in a northerly direction.
Travel service company TripAdvisor, Inc (NASDAQ: TRIP) saw its shares rally all through the end of 2023 and through much of March as well. But a 35% plunge over the past few days turned what was a promising start to the year into a nightmare. Making the drop an even more bitter pill for investors to swallow, TripAdvisor managed to beat expectations for its Q1 earnings on Wednesday. As is often the case, the devil was in the details, and the lack of any progress on a potential sale of the business was enough to send investors running for the exit.
But with an RSI that's currently just above 16 and a stock that's well off its low from Wednesday, there's some serious bounce potential at play here. To be sure, TripAdvisor is not without its risks, and it has arguably the most volatile short-term prospects of the three stocks listed here but arguably the greatest reward.
Just yesterday, Goldman Sachs reiterated their Buy rating and gave shares a fresh price target of $27. From the $17 they were trading at on Friday morning, that's pointing to more than 50% in potential upside.
Thank you for subscribing to DividendStocks.com's daily newsletter for dividend and income investors that covers ex-dividend stocks, new dividend declarations, dividend stock ideas, and the latest market news.
If you have questions about your subscription, feel free to contact our U.S. based support team via email at contact@marketbeat.com.
If you no longer wish to receive email from DividendStocks.com, you can unsubscribe.